Last checked at 23 Apr 2021 15:51
Hikma Pharmaceuticals PLC
Voting Results of 2021 Annual General Meeting
LONDON, 23 April 2021 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at 1 New Burlington Place, W1S 2HR, London on 23 April 2021 commenced at 1:00 pm. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 15 and 17 were passed as ordinary resolutions and Resolutions 16 and 18 to 22 were passed as special resolutions.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 24 February 2021) is set out below. The number of Ordinary Shares in issue on 23 April 2021 was 243,604,637. There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 230,771,404.
Resolution | Votes For | % | Votes Against | % | Total Cast | Withheld |
1. To receive the 2020 report and accounts | 176,723,133 | 100.0 | 16,692 | 0 | 176,739,825 | 1,537,096 |
2. To approve a final dividend of 34 cents per share | 178,275,824 | 100.0 | 152 | 0 | 178,275,976 | 945 |
3. To re-appoint PricewaterhouseCoopers LLP as auditors | 177,053,202 | 99.3 | 1,222,474 | 0.7 | 178,275,676 | 1,245 |
4.To authorise the Audit Committee to determine the auditors' remuneration | 178,174,755 | 99.9 | 100,365 | 0.1 | 178,275,120 | 1,801 |
5. To elect Douglas Hurt as a director | 174,859,594 | 98.1 | 3,414,131 | 1.9 | 178,273,725 | 3,196 |
6. To re-elect Said Darwazah as a director | 171,553,543 | 97.2 | 4,923,908 | 2.8 | 176,477,451 | 1,799,470 |
7. To re-elect Siggi Olafsson as a director | 176,112,071 | 98.8 | 2,163,336 | 1.2 | 178,275,407 | 1,514 |
8. To re-elect Mazen Darwazah as a director | 171,246,066 | 96.1 | 6,949,669 | 3.9 | 178,195,735 | 81,186 |
9. To re-elect Patrick Butler as a director | 172,831,258 | 97.0 | 5,434,621 | 3.1 | 178,265,879 | 11,041 |
10.To re-elect Ali Al-Husry as a director | 175,142,703 | 98.3 | 3,053,032 | 1.7 | 178,195,735 | 81,186 |
11. To re-elect Dr. Pamela Kirby as a director | 167,790,753 | 95.1 | 8,655,778 | 4.9 | 176,446,531 | 1,830,390 |
12. To re-elect John Castellani as a director | 175,101,327 | 98.9 | 1,975,760 | 1.1 | 177,077,087 | 1,199,834 |
13. To re-elect Nina Henderson as a director | 175,403,863 | 98.4 | 2,871,070 | 1.6 | 178,274,933 | 1,988 |
14. To re-elect Cynthia Schwalm as a director | 154,099,252 | 86.5 | 24,120,681 | 13.5 | 178,219,933 | 56,988 |
15. To approve the remuneration report for the year ended 31 December 2020 | 160,014,990 | 90.4 | 17,063,364 | 9.6 | 177,078,354 | 1,198,566 |
16. To approve the adoption of the new articles of association for the Company | 177,680,870 | 99.7 | 593,294 | 0.3 | 178,274,164 | 2,757 |
17. Authority to allot shares | 154,848,864 | 86.9 | 23,426,822 | 13.1 | 178,275,686 | 1,235 |
18. To dis-apply pre-emption rights for general purposes | 177,563,944 | 99.6 | 711,824 | 0.4 | 178,275,768 | 1,153 |
19. To dis-apply pre-emption rights for an acquisition or other capital investment | 174,606,709 | 97.9 | 3,668,585 | 2.1 | 178,275,294 | 1,627 |
20. To authorise the Company to purchase its own shares | 176,712,127 | 99.2 | 1,480,842 | 0.8 | 178,192,969 | 83,952 |
21. To authorise the Company to hold general meetings on no less than 14 clear days' notice | 169,544,820 | 95.1 | 8,731,027 | 4.9 | 178,275,847 | 1,074 |
Declaration of final dividend
The dividend of 34 cents per share will be paid on 26 April 2021 to shareholders on the register on 19 March 2021. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.3762998 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.709JD.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Peter Speirs Company Secretary
| +44 20 7399 2670 |
Susan Ringdal EVP, Strategic Planning and Global Affairs
| +44 20 7399 2670
|
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.